alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<Page>

                                                                   EXHIBIT 31.01

                     RULE 13a-14(a)/15d-14(a) CERTIFICATIONS

I, Robert M. Alderman, certify that:

1. I have reviewed this report on Form 10-Q of ML JWH Strategic Allocation Fund
L.P.;

2. Based on my knowledge, this report does not contain any untrue statement of a
material fact or omit to state a material fact necessary to make the statements
made, in light of the circumstances under which such statements were made, not
misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial
information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as
of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

   a) Designed such disclosure controls and procedures, or caused such
   disclosure controls and procedures to be designed under our supervision, to
   ensure that material information relating to the registrant, including its
   consolidated subsidiaries, is made known to us by others within those
   entities, particularly during the period in which this report is being
   prepared;

   b) Evaluated the effectiveness of the registrant's disclosure controls and
   procedures and presented in this report our conclusions about the
   effectiveness of the disclosure controls and procedures, as of the end of the
   period covered by this report based on such evaluation;

   c) Disclosed in this report any change in the registrant's internal control
   over financial reporting that occurred during the registrant's most recent
   fiscal quarter that has materially affected, or is reasonably likely to
   materially affect, the registrant's internal control over financial
   reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our
most recent evaluation of internal control over financial reporting, to the
registrant's auditors and the audit committee of registrant's board of directors
(or persons performing the equivalent functions):

   a) All significant deficiencies and material weaknesses in the design or
   operation of internal control over financial reporting which are reasonably
   likely to adversely affect the registrant's ability to record, process,
   summarize and report financial information; and

   b) Any fraud, whether or not material, that involves management or other
   employees who have a significant role in the registrant's internal control
   over financial reporting.


Date: November 14, 2005
-----------------------

By /s/ ROBERT M. ALDERMAN
   ----------------------
Robert M. Alderman
Chief Executive Officer, President and Manager
(Principal Executive Officer)
```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 6606 Introduced in House (IH)]

<DOC>

118th CONGRESS
  1st Session
                                H. R. 6606

    To amend the Export Control Reform Act of 2018 relating to the 
                          statement of policy.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                            December 5, 2023

Mrs. Radewagen introduced the following bill; which was referred to the 
                      Committee on Foreign Affairs

_______________________________________________________________________

                                 A BILL

 
    To amend the Export Control Reform Act of 2018 relating to the 
                          statement of policy.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. STATEMENT OF POLICY.

    Section 1752(2) of the Export Control Reform Act of 2018 (50 U.S.C. 
4811(2)) is amended by adding at the end the following:
                    ``(H) To protect the trade secrets of the United 
                States, its people, and its industrial base either 
                related to items subject to control by the Secretary 
                pursuant to this part or when the subject of economic 
                espionage as described in section 1831 of title 18, 
                United States Code.''.
                                 <all>
```
<PAGE>   1


EXHIBIT 15.1

                     INDEPENDENT ACCOUNTANTS' REVIEW REPORT

The Board of Directors and Stockholders
NCS HealthCare, Inc. and Subsidiaries


We have reviewed the accompanying condensed consolidated balance sheet of NCS
HealthCare, Inc. and subsidiaries (the Company) as of September 30, 1998, and
the related condensed consolidated statements of income and cash flows for the
three-month periods ended September 30, 1998 and 1997. These financial
statements are the responsibility of the Company's management.

We conducted our reviews in accordance with standards established by the
American Institute of Certified Public Accountants. A review of interim
financial information consists principally of applying analytical procedures to
financial data, and making inquiries of persons responsible for financial and
accounting matters. It is substantially less in scope than an audit conducted in
accordance with generally accepted auditing standards, which will be performed
for the full year with the objective of expressing an opinion regarding the
financial statements taken as a whole. Accordingly, we do not express such an
opinion.

Based on our reviews, we are not aware of any material modifications that should
be made to the accompanying condensed consolidated financial statements referred
to above for them to be in conformity with generally accepted accounting
principles.

We have previously audited, in accordance with generally accepted auditing
standards, the consolidated balance sheet of NCS HealthCare, Inc. and
subsidiaries as of June 30, 1998, and the related consolidated statements of
income, stockholders' equity and cash flows for the year then ended, not
presented herein, and in our report dated August 6, 1998, we expressed an
unqualified opinion on those consolidated financial statements. In our opinion,
the information set forth in the accompanying condensed consolidated balance
sheet as of June 30, 1998 is fairly stated, in all material respects, in
relation to the consolidated balance sheet from which it has been derived.


Cleveland, Ohio                                            /s/ Ernst & Young LLP
October 28, 1998

                                       15
<PAGE>   2
EXHIBIT 15.2

October 28, 1998

The Board of Directors and Stockholders
NCS HealthCare, Inc. and Subsidiaries


We are aware of the incorporation by reference in the Registration Statements
(Form S-8 No. 333-49417; Form S-3 No. 333-63437; Form S-3 No. 333-47293; Form
S-3/A No. 333-29565 and Form S-3/A No. 333-35551) of NCS HealthCare, Inc. of
our report dated October 28, 1998, relating to the unaudited condensed
consolidated interim financial statements of NCS HealthCare, Inc. and
subsidiaries that are included in its Form 10-Q for the quarter ended September
30, 1998.

                                                /s/ Ernst & young LLP




                                      16
---

EXHIBIT 32.1

CERTIFICATIONS PURSUANT TO 
  18 U.S.C. SECTION 1350, 
  AS ADOPTED PURSUANT TO 
  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Banyan Corporation (the "Company")
  on Form 10-KSB for the year ended December 31, 2004, as filed with the Securities
  and Exchange Commission on the date hereof (the "Report"), I, Michael Gelmon,
  Chief Executive Officer, certify, pursuant to 18 U.S.C. Section 1350, as adopted
  pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

| | (1) | The Report fully complies with the requirements of section
      13(a) or 15(d) of the Securities Exchange Act of 1934; and                                                                                        
| | --- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
| |     |                                                                                                                                                                                                                    
| | (2) | The information contained in the Report fairly presents,
      in all material respects, the financial condition and result of operations
      of the Company, as of, and for the periods presented in the Report.

/s/ Michael Gelmon 
  Michael Gelmon 
  Chief Executive Officer 
  January 19, 2006

A signed original of this written statement required by Section 906 has been provided to Banyan Corporation and will be retained by Banyan Corporation and furnished to the Securities and Exchange Commission or its staff upon request.

---
Exhibit 32.1

iDNA, INC.CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICERPURSUANT TO 18 U.S.C. 1350(SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002)

I, James J. McNamara, Chief Executive Officer of iDNA, Inc., a Delaware corporation (the ‘‘Registrant’’), in connection with the Registrant’s Quarterly Report on Form 10-Q for the period ended April 30, 2007, as filed with the Securities and Exchange Commission on the date hereof (the ‘‘Report’’), do hereby represent, warrant and certify pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

(1)    The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2)    The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.

|                                                                                                                                               |  |  |        |
|-----------------------------------------------------------------------------------------------------------------------------------------------|--|--|--------|
| /s/ James J. McNamara                     |  |  |   |
| Name: James J. McNamaraTitle: Chief Executive Officer(principal executive officer)                                                            |  |  |   |
| Date: June 12, 2007                                                                                                                 |  |  |   |
|                                                                                                                                               |

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to iDNA, Inc. and will be retained by iDNA, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

33

----
#### Cooper v. Wilson et al.

1. Practice: dismissal as to part of causes of action. Where plaintiff brought an action in three counts upon as many promissory notes, and sought a decree foreclosing a mortgage securing the notes, it was his privilege to dismiss as to two of the counts.

2. Practice on Appeal: less than $100. Where a plaintiff has dismissed as to some of his causes of action, and less than $100 is left in controversy, and judgment is rendered therefor, the defendant-cannot appeal to this court without the certificate of the trial judge.

*205
      *Appeal from IÁnrí Circuit Court.*

Thursday, March 10.

This is an appeal from a judgment and a decree for the foreclosure of a mortgage upon certain real estate.

*Geo. W. Wilson,*for appellants.

*Frank G. Clark,*for appellee.

Rothrock, J.

The plaintiff filed a petition in equity in three counts upon three, separate promissory notes, and he demanded a decree for the foreclosure, of a mortgage to secure the same. As to the first note, the defendant pleaded a tender of what he admitted to be due, and the difference between the tender and the amount claimed in that count of the petition was but a few dollars. The plaintiff dismissed his action as to the other notes, and the court rendered judgment against defendants on the first note for some eight or ten dollars more than the tender. Counsel for appellants appear to be dissatisfied because the plaintiff was permitted to dismiss his action as to the two last notes. We cannot understand why a plaintiff may not at any time withdraw or dismiss one of more of the causes of action in his petition. After the dismissal the amount-in controversy, as shown by the pleadings, was less than $100, and appellants present this appeal without the certificate of the trial judge, as required by statute. In such case, the certificate is requisite to confer jurisdiction on the court. We cannot entertain the appeal.

Dismissed.
SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549


                                   FORM 10-Q/A
                                 Amendment No. 1

             QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

                For the quarterly period ended September 30, 1996

                         Commission File Number 0-27742

                               CYLINK CORPORATION
             (Exact name of registrant as specified in its charter)

               California                                95-3891600
        (State or other jurisdiction of               (I.R.S. Employer
        incorporation or organization)             Identification Number)

                                910 Hermosa Court
                           Sunnyvale, California 94086
                    (Address of principal executive offices)

                                 (408) 735-5800
              (Registrant's telephone number, including area code)


     Indicate  by check mark  whether the  registrant  (1) has filed all reports
required to be filed by Sections 13 or 15(d) of the  Securities  Exchange Act of
1934  during  the  preceding  12 months  (or for such  shorter  period  that the
registrant was required to file such reports),  and (2) has been subject to such
filing requirements for the past 90 days.

                (1)     YES        X            NO
                                 -----                 -----
                (2)     YES        X            NO
                                 -----                 -----

     As of September 30, 1996, there were 25,448,132  shares of the Registrant's
common stock outstanding.

<PAGE>

                                   SIGNATURES

         Pursuant to the  requirements  of the Securities  Exchange Act of 1934,
the  registrant  has duly  caused  this report to be signed on its behalf by the
undersigned thereunto duly authorized.

Date: November 14, 1996                        CYLINK CORPORATION
                                               (Registrant)


                                               By: /s/ John H. Daws
                                                  ------------------------------
                                                   John H. Daws
                                                   Vice President of Finance
                                                   and Administration and
                                                   Chief Financial Officer
                                                   (Duly Authorized Officer
                                                   and Principal Financial
                                                   Officer)
                                                
<PAGE>
                                 EXHIBIT INDEX



Exhibits and Reports on Form 10Q/A



     Exhibit 27       Financial Data Schedule
```

[Federal Register Volume 87, Number 38 (Friday, February 25, 2022)]
[Notices]
[Page 10771]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-03953]

-----------------------------------------------------------------------

DEPARTMENT OF COMMERCE

Foreign-Trade Zones Board

[B-05-2022]

Foreign-Trade Zone (FTZ) 99--Wilmington, Delaware, Notification 
of Proposed Production Activity AstraZeneca Pharmaceuticals, LP 
(Pharmaceutical Products), Newark, Delaware

    AstraZeneca Pharmaceuticals, LP submitted a notification of 
proposed production activity to the FTZ Board (the Board) for its 
facility in Newark, Delaware within Subzone 99D. The notification 
conforming to the requirements of the Board's regulations (15 CFR 
400.22) was received on February 16, 2022.
    Pursuant to 15 CFR 400.14(b), FTZ production activity would be 
limited to the specific foreign-status materials and specific finished 
products described in the submitted notification (summarized below) and 
subsequently authorized by the Board. The benefits that may stem from 
conducting production activity under FTZ procedures are explained in 
the background section of the Board's website--accessible via 
www.trade.gov/ftz. The proposed finished products and materials would 
be added to the production authority that the Board previously approved 
for the operation, as reflected on the Board's website.
    The proposed finished products include: BRILINTA (ticagrelor) 
tablets; LYNPARZA (olaparib) tablets; SEROQUEL IR (quetiapine fumarate) 
tablets; and, SEROQUEL XR (quetiapine fumarate) tablets (duty-free).
    The proposed foreign-status materials include: Anastrozole active 
pharmaceutical ingredient (API); olaparib API; quetiapine fumarate API; 
and, ticagrelor API (duty rates 6.5%). The request indicates that 
olaparib API and ticagrelor API are subject to duties under Section 301 
of the Trade Act of 1974 (Section 301), depending on the country of 
origin. The applicable Section 301 decisions require subject 
merchandise to be admitted to FTZs in privileged foreign status (19 CFR 
146.41).
    Public comment is invited from interested parties. Submissions 
shall be addressed to the Board's Executive Secretary and sent to: 
[email protected]. The closing period for their receipt is April 6, 2022.
    A copy of the notification will be available for public inspection 
in the ``Online FTZ Information System'' section of the Board's 
website.
    For further information, contact Christopher Wedderburn at 
[email protected].

    Dated: February 18, 2022.
Andrew McGilvray,
Executive Secretary.
[FR Doc. 2022-03953 Filed 2-24-22; 8:45 am]
BILLING CODE 3510-DS-P
```
#### Eliza Colt, Respondent, *v.*The Sixth Avenue Railroad Company, Appellant.

It is not enough to justify a nonsuit that a court upon a case made, might in the exercise of its discretion grant anew trial. It is only where there is no evidence in law, which, if believed, will sustain a verdict, that the court is called npon to nonsuit; and the evidence may be sufficient in law to sustain a verdict, although so greatly against the apparent weight of evidence as to justify the granting of a new trial.

(Argued May 1, 1872;

decided May 21, 1872.)

Action to recover damages for injuries sustained by plaintiff while alighting from defendant’s car. The car started upon the usual signal from the conductor, while the plaintiff was in the act of alighting, and before she was entirely free, her feet having reached the ground, but her dress being caught, she was in consequence violently thrown down and received the injury complained of.

A motion was made for a nonsuit, which was denied. Various questions as to the reception and rejection of evidence were also decided.

*James M. Smith*for the appellant.

*G. M. Spew*for the respondent.

*672Allen, J.,

reads opinion for affirmance.

All concur, except Rapallo, J., not voting.

Judgment affirmed, with costs.
```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 6474 Referred in Senate (RFS)]

<DOC>
118th CONGRESS
  2d Session
                                H. R. 6474

_______________________________________________________________________

                   IN THE SENATE OF THE UNITED STATES

                           September 25, 2024

    Received; read twice and referred to the Committee on Energy and 
                           Natural Resources

_______________________________________________________________________

                                 AN ACT

 
     To amend the Energy Policy Act of 2005 to expedite geothermal 
 exploration and development in previously studied or developed areas.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. NEPA REVIEW.

    Section 390 of the Energy Policy Act of 2005 (42 U.S.C. 15942) is 
amended--
            (1) in subsection (a), by inserting ``, or the Geothermal 
        Steam Act of 1970 (30 U.S.C. 1001 et seq.) for the purpose of 
        exploration or development of geothermal resources'' after ``or 
        gas''; and
            (2) in subsection (b)--
                    (A) in paragraph (2), by striking ``or gas'' and 
                inserting ``, gas, or geothermal''; and
                    (B) in paragraph (3), by striking ``or gas'' and 
                inserting ``, gas, or geothermal''.

            Passed the House of Representatives September 24, 2024.

            Attest:

                                             KEVIN F. MCCUMBER,

                                                                 Clerk.
```
<TABLE> <S> <C>

<PAGE>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM PACIFIC
COAST APPAREL COMPANY INC dba Aca Joe AND IS QUALIFIED IN ITS ENTIRETY BY
REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          SEP-30-1996
<PERIOD-START>                             OCT-01-1996
<PERIOD-END>                               DEC-31-1996
<CASH>                                          20,498
<SECURITIES>                                 3,022,004
<RECEIVABLES>                                        0
<ALLOWANCES>                                         0
<INVENTORY>                                    539,083
<CURRENT-ASSETS>                             3,717,656
<PP&E>                                         120,965
<DEPRECIATION>                                  11,544
<TOTAL-ASSETS>                               3,840,859
<CURRENT-LIABILITIES>                          358,652
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                     5,806,868
<OTHER-SE>                                 (2,326,710)
<TOTAL-LIABILITY-AND-EQUITY>                 3,840,859
<SALES>                                         66,022
<TOTAL-REVENUES>                                66,022
<CGS>                                           27,000
<TOTAL-COSTS>                                  379,425
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                              11,199
<INCOME-PRETAX>                              (351,602)
<INCOME-TAX>                                       800
<INCOME-CONTINUING>                          (352,402)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 (352,402)
<EPS-PRIMARY>                                    (.12)
<EPS-DILUTED>                                    (.12)
        

</TABLE>